HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Distributions Of All Amounts Of PSE Would Be Regulated Under DEA Rule

This article was originally published in The Tan Sheet

Executive Summary

The Drug Enforcement Administration continues developing enforcement tools to implement the Combat Meth Act with a Nov. 20 notice of proposed rulemaking to regulate the distribution of all amounts of pseudoephedrine and phenylpropanolamine

You may also be interested in...

PSE reporting threshold erased

The distribution of all amounts of pseudoephedrine and phenylpropanolamine fall under the Drug Enforcement Administration's enforcement, according to a final rule published July 7 in the Federal Register. The rule, which takes effect Aug. 6, is the latest step in DEA's implementation of the Combat Methamphetamine Epidemic Act. It eliminates the current threshold of 2.2 pounds to trigger DEA's reporting and recordkeeping requirements, according to a July 7 Federal Register notice. DEA says the unregulated distribution of any amount of PSE increases the likelihood the substance could be diverted to use for illicit meth manufacturing. DEA also imposed retail sales limits and tracking requirements under provisions of Combat Meth (1"The Tan Sheet" Nov. 26, 2007)

Senate Passes Bill Enforcing Distributor Compliance With Combat Meth Act

The Senate passed a bill Feb. 11 that requires distributors of pseudoephedrine-containing OTC drugs to sell only to retailers who verify they comply with the Combat Meth Act or who are registered with the DEA

First Arrest Under Combat Meth Act Generated By Local Database In NY

The first arrest for a violation of the Combat Meth Act's limits on retail purchases of pseudoephedrine-containing drugs occurred in western New York state, where investigators manually compile a database to track PSE sales in their county

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts